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Objective
In our previous experiments a decrease of the MDMA-
induced 5-HT syndrome (HTS) was observed following
repeated administration of the dextrorotatory (d) enanti-
omer of MDMA. The aim of the present study was to
examine how the dopamine agonist-induced stereotyped
behaviour (SB) alters following single or repeated d-
MDMA treatment.
Methods
Wistar male rats were treated with single or repeated (4
times with 2 hours intervals) doses (10 mg/kg) of d-
MDMA. Three, 7 and 14 days later the intensity of d-
MDMA-induced HTS and SB was examined. The SB-
inducing effect of d-amphetamine (AM) and apomor-
phine (APO) was also checked.
Results
(1) Following repeated administration of d-MDMA the
intensity of MDMA-induced HTS decreased while that of
SB increased. (2) Single dose pretreatment with d-MDMA
did not influence the d-MDMA-induced HTS but
enhanced the SB. (3) The d-AM-induced SB also increased
while the APO-induced SB did not change.
Conclusion
A single dose of d-MDMA, which, in contrast to the
repeated treatment, did not alter the 5-HT-related behav-
iour, may already result in development of DA sensitiza-
tion.
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